Showing 1 - 7 results of 7 for search 'Sébastien Calbo', query time: 0.04s Refine Results
  1. 1
    Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants

    Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants by Jaber Dehghani, Ali Movafeghi, Elodie Mathieu-Rivet, Narimane Mati-Baouche, Sébastien Calbo, Patrice Lerouge, Muriel Bardor

    Published 2022-10-01
    Get full text
    Article
  2. 2
    The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab

    The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab by Marie-Laure Golinski, Alexandre Lemieux, Maud Maho-Vaillant, Marion Barray, Laurent Drouot, Damien Schapman, Marie Petit, Michael Hertl, Olivier Boyer, Sébastien Calbo, Pascal Joly, Vivien Hébert

    Published 2022-03-01
    Get full text
    Article
  3. 3
    CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors

    CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors by Marie-Laure Golinski, Marie-Laure Golinski, Mélanie Demeules, Céline Derambure, Gaetan Riou, Maud Maho-Vaillant, Maud Maho-Vaillant, Olivier Boyer, Olivier Boyer, Pascal Joly, Pascal Joly, Sébastien Calbo

    Published 2020-02-01
    Get full text
    Article
  4. 4
    Longitudinal Pathogenic Properties and <i>N</i>-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid Treatment

    Longitudinal Pathogenic Properties and <i>N</i>-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid Treatment by Marie Petit, Marie-Laure Walet-Balieu, Damien Schapman, Marie-Laure Golinski, Carole Burel, Marion Barray, Laurent Drouot, Maud Maho-Vaillant, Vivien Hébert, Olivier Boyer, Muriel Bardor, Pascal Joly, Sébastien Calbo

    Published 2021-10-01
    Get full text
    Article
  5. 5
    IgG <i>N-</i>glycosylation from Patients with Pemphigus Treated with Rituximab

    IgG <i>N-</i>glycosylation from Patients with Pemphigus Treated with Rituximab by Guillaume Font, Marie-Laure Walet-Balieu, Marie Petit, Carole Burel, Maud Maho-Vaillant, Vivien Hébert, Philippe Chan, Manuel Fréret, Olivier Boyer, Pascal Joly, Sébastien Calbo, Muriel Bardor, Marie-Laure Golinski

    Published 2022-07-01
    Get full text
    Article
  6. 6
    Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen

    Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen by Vivien Hébert, Vivien Hébert, Marie Petit, Maud Maho-Vaillant, Maud Maho-Vaillant, Marie-Laure Golinski, Marie-Laure Golinski, Gaëtan Riou, Céline Derambure, Olivier Boyer, Pascal Joly, Pascal Joly, Sébastien Calbo

    Published 2019-08-01
    Get full text
    Article
  7. 7
    FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus

    FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus by Maud Maho-Vaillant, Maud Maho-Vaillant, Magdalena Sips, Marie-Laure Golinski, Marie-Laure Golinski, Gestur Vidarsson, Matthias Goebeler, Johanna Stoevesandt, Zsuzsanna Bata-Csörgő, Bianca Balbino, Peter Verheesen, Pascal Joly, Michael Hertl, Sébastien Calbo

    Published 2022-05-01
    Get full text
    Article

Search Tools: